Random pharmacokinetic profiles of EC-MPS in children with autoimmune disease

Pediatric Rheumatology

Volumn 8, Issue , 2010, Pages

  Filler, Guido ^a   Sharma, Ajay P ^a   Levy, Deborah M ^a   Yasin, Abeer ^a  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER;

AREA UNDER THE CURVE; ARTICLE; AUTOIMMUNE DISEASE; BIOEQUIVALENCE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG DOSAGE FORM COMPARISON; ENTERIC COATED TABLET; GLOMERULONEPHRITIS; HUMAN; MAXIMUM PLASMA CONCENTRATION; PEDIATRICS; PILOT STUDY; PRIORITY JOURNAL; SARCOIDOSIS; SYSTEMIC LUPUS ERYTHEMATOSUS; TIME TO MAXIMUM PLASMA CONCENTRATION;

EID: 76749122332     PISSN: None     EISSN: 15460096     Source Type: Journal    
DOI: 10.1186/1546-0096-8-1     Document Type: Article

References (15)

1. Allison AC. Mechanisms of action of mycophenolate mofetil. Lupus 2005, 14(Suppl 1):s2-8. 10.1177/096120330501400102, 15803924.
2. Appel GB, Contreras G, Dooley MA, Ginzler EM, Isenberg D, Jayne D, Li LS, Mysler E, Sánchez-Guerrero J, Solomons N, Wofsy D, . Aspreva Lupus Management Study Group Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol 2009, 20:1103-12. 10.1681/ASN.2008101028, 19369404, Aspreva Lupus Management Study Group.
3. Filler G, Hansen M, LeBlanc C, Lepage N, Franke D, Mai I, Feber J. Pharmacokinetics of mycophenolate mofetil for autoimmune disease in children. Pediatr Nephrol 2003, 18:445-9. 10.1007/s00467-003-1271-5, 12687454.
4. Filler G, Zimmering M, Mai I. Pharmacokinetics of mycophenolate mofetil are influenced by concomitant immunosuppression. Pediatr Nephrol 2000, 14:100-4. 10.1007/s004670050021, 10684356.
5. Zahr N, Amoura Z, Debord J, Hulot JS, Saint-Marcoux F, Marquet P, Piette JC, Lechat P. Pharmacokinetic study of mycophenolate mofetil in patients with systemic lupus erythematosus and design of Bayesian estimator using limited sampling strategies. Clin Pharmacokinet 2008, 47:277-84. 10.2165/00003088-200847040-00005, 18336056.
6. Roland M, Barbet C, Paintaud G, Magdelaine-Beuzelin C, Diot E, Halimi JM, Lebranchu Y, Nivet H, Büchler M. Mycophenolate mofetil in patients with systemic lupus erythematosus: a prospective pharmacokinetic study. Lupus 2009, 18:441-7. 10.1177/0961203308098631, 19318398.
7. Filler G, Buffo I. Safety considerations with mycophenolate sodium. Expert Opin Drug Saf 2007, 6:445-9. Review., 10.1517/14740338.6.4.445, 17688388.
8. Schutz E, Shipkova M, Armstrong VW, Niedmann PD, Weber L, Tonshoff B, Pethig K, Wahlers T, Braun F, Ringe B, Oellerich M. Therapeutic drug monitoring of mycophenolic acid: comparison of HPLC and immunoassay reveals new MPA metabolites. Transplant Proc 1998, 30:1185-7. 10.1016/S0041-1345(98)00201-2, 9636479.
9. Johnston A, He X, Holt DW. Bioequivalence of enteric-coated mycophenolate sodium and mycophenolate mofetil: a meta-analysis of three studies in stable renal transplant recipients. Transplantation 2006, 82:1413-8. 10.1097/01.tp.0000242137.68863.89, 17164710.
10. Darji P, Vijayaraghavan R, Thiagarajan CM, Sharma RK, Subbarao B, Pishardy R, Dakshinamurthy KV, Vijaykumar R, Abraham G, Bhaskar S, Agarwal L, Shah B, Abraham A, John M, Sampathkumar K, Das T, Umesh L, Sundar S, Ballal H, Jasuja S, Saxena S, Saha TK. Conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in renal transplant recipients with gastrointestinal tract disorders. Transplant Proc 2008, 40:2262-7. 10.1016/j.transproceed.2008.07.041, 18790208.
11. Traitanon O, Avihingsanon Y, Kittikovit V, Townamchai N, Kanjanabuch T, Praditpornsilpa K, Wongchinasri J, Tungsanga K, Eiam-Ong S. Efficacy of enteric-coated mycophenolate sodium in patients with resistant-type lupus nephritis: a prospective study. Lupus 2008, 17:744-51. 10.1177/0961203308090991, 18625653.
12. Perry TW, Christians U, Trotter JF, Bendrick-Peart J. Pharmacokinetics of enteric-coated mycophenolate sodium in stable liver transplant recipients. Clin Transplant 2007, 21:413-6. 10.1111/j.1399-0012.2007.00662.x, 17488394.
13. Gajarski RJ, Crowley DC, Zamberlan MC, Lake KD. Lack of correlation between MMF dose and MPA level in pediatric and young adult cardiac transplant patients: does the MPA level matter?. Am J Transplant 2004, 4:1495-500. 10.1111/j.1600-6143.2004.00534.x, 15307837.
14. Filler G. Abbreviated mycophenolic acid AUC from C0, C1, C2, and C4 is preferable in children after renal transplantation on mycophenolate mofetil and tacrolimus therapy. Transpl Int 2004, 17:120-5.
15. Le Meur Y, Büchler M, Thierry A, Caillard S, Villemain F, Lavaud S, Etienne I, Westeel PF, Hurault de Ligny B, Rostaing L, Thervet E, Szelag JC, Rérolle JP, Rousseau A, Touchard G, Marquet P. Individualized mycophenolate mofetil dosing based on drug exposure significantly improves patient outcomes after renal transplantation. Am J Transplant 2007, 7:2496-503. 10.1111/j.1600-6143.2007.01983.x, 17908276.